PCSA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Processa Pharmaceuticals Inc (PCSA) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The lack of positive financial performance, absence of significant trading trends, no recent news, and weak growth prospects make this stock less attractive for long-term investment. It is better to hold off for now.
The MACD is positive and expanding, indicating a bullish signal. However, the RSI is neutral at 78.976, and moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 2.858), suggesting limited upside potential in the short term.
NULL identified. No recent news or significant insider/hedge fund activity.
The stock has a 30% chance of declining by -1.65% in the next day, -4.23% in the next week, and -2.43% in the next month. Financial performance is weak, with negative EPS and net income.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income slightly improved to -$3,436,573 (up 1.53% YoY), but EPS dropped significantly by -92.99% YoY to -1.81. Gross margin is 0%, indicating no profitability.
No analyst rating or price target changes available.
